Tag: 上海品茶网MXG

Celgene’s beaten-down stock is cheap, but only if investors regain trust in its financial outlook

first_img @adamfeuerstein By Adam Feuerstein April 30, 2018 Reprints Log In | Learn More Tags biotechfinanceSTAT+ Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. About the Author Reprints Celgene’s beaten-down stock is cheap, but only if investors regain trust in its financial outlook GET STARTED STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. What’s included?center_img Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED Adam Feuerstein What is it? Kristoffer Tripplaar/SIPA via AP Senior Writer, Biotech Adam is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He’s also a co-host of “The Readout LOUD” podcast. [email protected] I hesitate to call any single earnings report a do-or-die event, but for troubled Celgene (CELG), Friday’s first-quarter financial update comes pretty close.Celgene CEO Mark Alles and his team must convince investors that the horrible run of mistakes that started last fall is finally over and won’t happen again. A positive regulatory update on the delayed multiple sclerosis drug candidate ozanimod would be welcome news. Adam’s Take last_img read more